ref_name,rx_name,iso_name,section,assay_name,potency_type,potency,cumulative_count,potency_upper_limit,potency_lower_limit,potency_unit,date_added
Miyakawa21,BNT_naive_1dose,S:614G,Figure 1E,hiVNT,inhibition,49,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_2dose,S:614G,Figure 1E,hiVNT,inhibition,98,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_1dose,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1E,hiVNT,inhibition,14,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_2dose,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1E,hiVNT,inhibition,98,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_1dose,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1E,hiVNT,inhibition,22,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_2dose,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1E,hiVNT,inhibition,85,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_1dose,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1E,hiVNT,inhibition,10,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_2dose,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1E,hiVNT,inhibition,95,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_1dose,S:152L+484K+614G+769V,Figure 1E,hiVNT,inhibition,30,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_2dose,S:152L+484K+614G+769V,Figure 1E,hiVNT,inhibition,96,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_1dose,S:95I+153I+154K+452R+484Q+614G+681R+1071H,Figure 1E,hiVNT,inhibition,36,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_2dose,S:95I+153I+154K+452R+484Q+614G+681R+1071H,Figure 1E,hiVNT,inhibition,96,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_1dose,S:13I+152C+452R+614G,Figure 1E,hiVNT,inhibition,35,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_2dose,S:13I+152C+452R+614G,Figure 1E,hiVNT,inhibition,97,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_1dose,S:5F+95I+253G+477N+614G+701V,Figure 1E,hiVNT,inhibition,44,105,100,40,percent,2021-10-19
Miyakawa21,BNT_naive_2dose,S:5F+95I+253G+477N+614G+701V,Figure 1E,hiVNT,inhibition,99,105,100,40,percent,2021-10-19
Miyakawa21,CP_1,S:614G,Figure 1F,hiVNT,inhibition,88,6,100,40,percent,2021-10-19
Miyakawa21,CP_2,S:614G,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,CP_3,S:614G,Figure 1F,hiVNT,inhibition,89,6,100,40,percent,2021-10-19
Miyakawa21,CP_4,S:614G,Figure 1F,hiVNT,inhibition,87,6,100,40,percent,2021-10-19
Miyakawa21,CP_5,S:614G,Figure 1F,hiVNT,inhibition,79,6,100,40,percent,2021-10-19
Miyakawa21,CP_6,S:614G,Figure 1F,hiVNT,inhibition,69,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_1,S:614G,Figure 1F,hiVNT,inhibition,98,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_2,S:614G,Figure 1F,hiVNT,inhibition,98,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_3,S:614G,Figure 1F,hiVNT,inhibition,97,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_4,S:614G,Figure 1F,hiVNT,inhibition,98,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_5,S:614G,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_6,S:614G,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_1,S:614G,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_2,S:614G,Figure 1F,hiVNT,inhibition,98,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_3,S:614G,Figure 1F,hiVNT,inhibition,98,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_4,S:614G,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_5,S:614G,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_6,S:614G,Figure 1F,hiVNT,inhibition,98,6,100,40,percent,2021-10-19
Miyakawa21,CP_7,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,88,6,100,40,percent,2021-10-19
Miyakawa21,CP_8,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,97,6,100,40,percent,2021-10-19
Miyakawa21,CP_9,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,68,6,100,40,percent,2021-10-19
Miyakawa21,CP_10,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,56,6,100,40,percent,2021-10-19
Miyakawa21,CP_11,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,40,6,100,40,percent,2021-10-19
Miyakawa21,CP_12,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,42,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_7,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,97,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_8,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_9,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_10,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_11,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_12,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_7,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,97,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_8,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_9,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_10,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_11,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_12,S:68del+69del+70del+144del+145del+501Y+570D+614G+681H+716I+982A+1118H,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,CP_13,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,11,6,100,40,percent,2021-10-19
Miyakawa21,CP_14,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,50,6,100,40,percent,2021-10-19
Miyakawa21,CP_15,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,46,6,100,40,percent,2021-10-19
Miyakawa21,CP_16,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,54,6,100,40,percent,2021-10-19
Miyakawa21,CP_17,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,15,6,100,40,percent,2021-10-19
Miyakawa21,CP_18,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,9,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_13,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_14,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,97,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_15,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,96,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_16,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,98,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_17,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,97,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_18,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,96,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_13,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_14,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,98,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_15,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,95,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_16,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,96,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_17,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,96,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_18,S:80A+242del+243del+244del+246I+417N+484K+501Y+614G+701V,Figure 1F,hiVNT,inhibition,95,6,100,40,percent,2021-10-19
Miyakawa21,CP_19,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,56,6,100,40,percent,2021-10-19
Miyakawa21,CP_20,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,78,6,100,40,percent,2021-10-19
Miyakawa21,CP_21,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,45,6,100,40,percent,2021-10-19
Miyakawa21,CP_22,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,68,6,100,40,percent,2021-10-19
Miyakawa21,CP_23,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,26,6,100,40,percent,2021-10-19
Miyakawa21,CP_24,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,29,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_19,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_20,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_21,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_22,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_23,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,97,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_1dose_24,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_19,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_20,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_21,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_22,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_23,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,99,6,100,40,percent,2021-10-19
Miyakawa21,BNT_CP_2dose_24,S:18F+20N+26S+138Y+190S+417T+484K+501Y+614G+655Y+1027I+1176F,Figure 1F,hiVNT,inhibition,100,6,100,40,percent,2021-10-19
